A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Clinical trial NCT06624085 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06624085
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-28
- Primary completion
- 2027-03-22
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.